Literature DB >> 31094471

Markers of dysbiosis in patients with ulcerative colitis and Crohn's disease.

N A Danilova1, S R Abdulkhakov1,2, T V Grigoryeva1, M I Markelova1, I Yu Vasilyev1, E A Boulygina1, M D Ardatskaya3, A V Pavlenko4, A V Tyakht5, A Kh Odintsova6, R A Abdulkhakov2.   

Abstract

AIM: The aim of the study was to study the taxonomic and functional composition of the gut microbiota in ulcerative colitis (UC) and Crohn's disease (CD) patients to identify key markers of dysbiosis in IBD.
MATERIALS AND METHODS: Fecal samples obtained from 95 IBD patients (78 UC and 17 CD) as well as 96 healthy volunteers were used for whole-genome sequencing carried out on the SOLiD 5500 W platform. Taxonomic profiling was performed by aligning the reeds, not maped on hg19, on MetaPhlAn2 reference database. Reeds were mapped using the HUNAnN2 algorithm to the ChocoPhlAn database to assess the representation of microbial metabolic pathways. Short-chain fatty acids (SCFA) level were measured in fecal samples by gas-liquid chromatographic analysis.
RESULTS: Changes in IBD patients gut microbiota were characterized by an increase in the representation of Proteobacteria and Bacteroidetes phyla bacteria and decrease in the number of Firmicutes phylum bacteria and Euryarchaeota phylum archaea; a decrease in the alpha-diversity index, relative representation of butyrate-producing, hydrogen-utilizing bacteria, and Methanobrevibacter smithii; increase in the relative representation of Ruminococcus gnavus in UC and CD patients and Akkermansia muciniphila in CD patients. Reduction of Butyryl-CoA: acetate CoA transferase gene relative representation in CD patients, decrease of absolute content of SCFA total number as well as particular SCFAs and main SCFAs ratio in IBD patients may indicate inhibition of functional activity and number of anaerobic microflora and/or an change in SCFA utilization by colonocytes.
CONCLUSION: the revealed changes can be considered as typical signs of dysbiosis in IBD patients and can be used as potential targets for IBD patients personalized treatment development.

Entities:  

Keywords:  Crohn's disease; dysbiosis; gut microbiota; short-chain fatty acids; ulcerative colitis; whole-genome sequencing

Mesh:

Year:  2019        PMID: 31094471     DOI: 10.26442/00403660.2019.04.000211

Source DB:  PubMed          Journal:  Ter Arkh        ISSN: 0040-3660            Impact factor:   0.467


  13 in total

1.  Alterations of Akkermansia muciniphila in the inflammatory bowel disease patients with washed microbiota transplantation.

Authors:  Ting Zhang; Pan Li; Xia Wu; Gaochen Lu; Cicilia Marcella; Xinghui Ji; Guozhong Ji; Faming Zhang
Journal:  Appl Microbiol Biotechnol       Date:  2020-10-16       Impact factor: 4.813

Review 2.  The potential of Akkermansia muciniphila in inflammatory bowel disease.

Authors:  Ting Zhang; Xinghui Ji; Gaochen Lu; Faming Zhang
Journal:  Appl Microbiol Biotechnol       Date:  2021-07-27       Impact factor: 4.813

3.  Butyric Acid Increases the Therapeutic Effect of EHLJ7 on Ulcerative Colitis by Inhibiting JAK2/STAT3/SOCS1 Signaling Pathway.

Authors:  Xiaonan Tang; Xiang Li; Yufei Wang; ZhiHui Zhang; AnJun Deng; WenJie Wang; Haijing Zhang; Hailin Qin; LianQiu Wu
Journal:  Front Pharmacol       Date:  2020-01-22       Impact factor: 5.810

4.  MICROBIOTA INSIGHTS IN CLOSTRIDIUM DIFFICILE INFECTION AND INFLAMMATORY BOWEL DISEASE.

Authors:  C Rodríguez; E Romero; L Garrido-Sanchez; G Alcaín-Martínez; R J Andrade; B Taminiau; G Daube; E García-Fuentes
Journal:  Gut Microbes       Date:  2020-03-04

5.  Fecal 1H-NMR Metabolomics: A Comparison of Sample Preparation Methods for NMR and Novel in Silico Baseline Correction.

Authors:  Catherine L J Brown; Hannah Scott; Crystal Mulik; Amy S Freund; Michael P Opyr; Gerlinde A S Metz; G Douglas Inglis; Tony Montina
Journal:  Metabolites       Date:  2022-02-05

6.  Diversity and Adaptations of Escherichia coli Strains: Exploring the Intestinal Community in Crohn's Disease Patients and Healthy Individuals.

Authors:  Maria N Siniagina; Maria I Markelova; Eugenia A Boulygina; Alexander V Laikov; Dilyara R Khusnutdinova; Sayar R Abdulkhakov; Natalia A Danilova; Alfiya H Odintsova; Rustam A Abdulkhakov; Tatyana V Grigoryeva
Journal:  Microorganisms       Date:  2021-06-15

7.  Effect of long-term methylene blue treatment on the composition of mouse gut microbiome and its relationship with the cognitive abilities of mice.

Authors:  Artem P Gureev; Mikhail Yu Syromyatnikov; Daria A Ignatyeva; Valeria V Valuyskikh; Sergey A Solodskikh; Anna V Panevina; Maria V Gryaznova; Anastasia V Kokina; Vasily N Popov
Journal:  PLoS One       Date:  2020-11-18       Impact factor: 3.240

8.  Inflammatory Bowel Disease-Associated Changes in the Gut: Focus on Kazan Patients.

Authors:  Giuseppe Lo Sasso; Lusine Khachatryan; Athanasios Kondylis; James N D Battey; Nicolas Sierro; Natalia A Danilova; Tatiana V Grigoryeva; Maria I Markelova; Dilyara R Khusnutdinova; Alexander V Laikov; Ilnur I Salafutdinov; Yulia D Romanova; Mariia N Siniagina; Ilya Yu Vasiliev; Eugenia A Boulygina; Valeriya V Solovyeva; Ekaterina E Garanina; Kristina V Kitaeva; Konstantin Y Ivanov; Darja S Chulpanova; Konstantin S Kletenkov; Alina R Valeeva; Alfiya Kh Odintsova; Maria D Ardatskaya; Rustam A Abdulkhakov; Nikolai V Ivanov; Manuel C Peitsch; Julia Hoeng; Sayar R Abdulkhakov
Journal:  Inflamm Bowel Dis       Date:  2021-02-16       Impact factor: 5.325

9.  Nrf2/ARE Activators Improve Memory in Aged Mice via Maintaining of Mitochondrial Quality Control of Brain and the Modulation of Gut Microbiome.

Authors:  Irina S Sadovnikova; Artem P Gureev; Daria A Ignatyeva; Maria V Gryaznova; Ekaterina V Chernyshova; Ekaterina P Krutskikh; Anastasia G Novikova; Vasily N Popov
Journal:  Pharmaceuticals (Basel)       Date:  2021-06-23

10.  High-Salt Diet Induces Depletion of Lactic Acid-Producing Bacteria in Murine Gut.

Authors:  Ibrahim Hamad; Alessio Cardilli; Beatriz F Côrte-Real; Aleksandra Dyczko; Jaco Vangronsveld; Markus Kleinewietfeld
Journal:  Nutrients       Date:  2022-03-10       Impact factor: 5.717

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.